Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BYDrug Design, Development and Therapy

Efficacy, Safety, and Immunogenicity of Biosimilar versus Reference Adalimumab in Methotrexate-Refractory Rheumatoid Arthritis: A Phase III Comparative Study

5 affiliations
  1. 1Clinical Affairs Division
  2. 2Dept of Clinical Immunology & Rheumatology
  3. 3Medical Affairs Department
  4. 4Bioanalytical Laboratory
  5. 5Rheumatology

Abstract

Veerendra Kumar Panuganti,1 Parasar Ghosh,2 Mamatha Reddy Dundigalla,3 Venkata Ramalingayya Grandhi,3 Pavan Kumar Madala,4 Javeed Mohammad,1 Sanyasirao KSSVV,1 Sridevi Khambhampaty,5 Firdaus Fatima6 1Clinical Affairs Division, Shilpa Medicare Limited, Hyderabad, Telangana, 500076, India; 2Institute of Postgraduate, Medical Education and Research, Kolkata, West Bengal, 700020, India; 3Medical Affairs Department, Shilpa Medicare Limited, Hyderabad, Telangana, 500076, India; 4Bioanalytical Laboratory, Shilpa Medicare Ltd, Hyderabad, Telangana, 500076, India; 5Shilpa Biologicals Private Limited, Dharwad, Karnataka, 580011, India; 6St. Theresa’s Hospital, Hyderabad, Telangana, 500038, IndiaCorrespondence: Veerendra Kumar Panuganti, Clinical Affairs Division, Shilpa Medicare Limited, Mallapur, Nacharam, Hyderabad, Telangana, 500076, India, Email [email protected]: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by dysregulated immune responses, persistent synovial inflammation, and involvement of multiple pro-inflammatory mediators, leading to progressive joint damage. Although adalimumab has substantially improved RA management, high-cost limits patient access. Biosimilars offer accessibility, while maintaining comparable efficacy and safety.Objective: To compare efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of test adalimumab (Oriadali®) a proposed adalimumab biosimilar, with reference adalimumab (Humira®) in Indian patients with active RA inadequately controlled by methotrexate (MTX).Methods: In this prospective, randomized, double-blind, multicenter, active-controlled Phase III study, 201 patients with active RA were randomized (2:1) to receive test adalimumab (n=134) or reference adalimumab (n=67). The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response at Week 24, assessed using a pre-specified non-inferiority margin of 28%. Secondary endpoints included ACR 20 response at Week 12, ACR50/70 at Week 24, Disease Activity Score based on 28 joints (DAS-28), C-reactive protein (CRP), Health Assessment Questionnaire-Disability Index (HAQ-DI), PK, PD, safety, and immunogenicity using anti-drug antibody (ADA) assessment.Results: ACR 20 responses at Week 24 were achieved by 120/121 (99.2%) patients receiving test adalimumab and 63/63 (100.0%) patients receiving reference adalimumab (difference of − 0.01 95% CI: − 0.03 to 0.02; p=0.4693), demonstrating non-inferiority. At Week 12, ACR20 responses were achieved by 90.1% and 92.1% of patients in both groups, respectively. At Week 24, ACR50 responses were 61.2% versus 57.1%, and ACR70 responses were 32.3% versus 33.3%. DAS28, CRP and HAQ-DI improved similarly in both groups. PK exposure was comparable, with all parameters within bioequivalence limits (T/R ratio of Cmax 100.16%; AUC0–t 102.99%), Changes in IL-6, TNF- α and immunogenicity were comparable between groups. Most Adverse events (AEs) were mild to moderate, with no serious adverse events reported.Conclusion: Test adalimumab biosimilar demonstrated comparable efficacy, safety PK, PD, and immunogenicity profiles to reference adalimumab, supporting its use in patients with active RA receiving methotrexate.Trial Registration: CTRI/2021/07/034531.Keywords: RA, Adalimumab, biosimilar, test Adalimumab, reference Adalimumab, TNF-α, MTX, PK, ADA, treatment outcome

Related

  1. Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity
    Dongyang Li, Yuhuan Jiao, Kun Wu +3
    Current therapeutic research, clinical and experimentalPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Analytical Characterization, Pharmacokinetics, Safety, and Preliminary Immunogenicity of GNR-062, an Agalsidase Beta Biosimilar Candidate, in Healthy Male Volunteers.
    Ivan Lyagoskin, Maksim Smolov, Oksana Markova +6
    Biotech (Basel (Switzerland))Peer-reviewedCC BYFull textPhysiologyEurope PMC
  3. Intra-Individual Comparative Study of Methotrexate versus Triamcinolone Acetonide Delivered via Microneedling for Recalcitrant Alopecia Areata.
    Mofreh Mansour, Refaat R Mohamed, Athar Fathy Abodief Mohamed +1
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Comparative immunogenicity of several inactivated influenza vaccines among healthcare workers in Hong Kong
    W. W. Lim, L. Touyon, L. Mak +6
    medRxivPreprintCC BYFull textInfectious diseasemedRxiv
  5. Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025
    K. M. Sumner, E. K. Noble, L. B. Grant +23
    medRxivPreprintCC0Full textEpidemiology & public healthmedRxiv
BibTeX
@article{panuganti2026efficacy,
  title = {{Efficacy, Safety, and Immunogenicity of Biosimilar versus Reference Adalimumab in Methotrexate-Refractory Rheumatoid Arthritis: A Phase III Comparative Study}},
  author = {Panuganti VK and Ghosh P and Dundigalla MR and Ramalingayya Grandhi V and Madala PK and Mohammad J and KSSVV S and Khambhampaty S and Fatima F},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  month = nov,
  url = {https://www.dovepress.com/efficacy-safety-and-immunogenicity-of-biosimilar-versus-reference-adal-peer-reviewed-fulltext-article-DDDT},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Efficacy, Safety, and Immunogenicity of Biosimilar versus Reference Adalimumab in Methotrexate-Refractory Rheumatoid Arthritis: A Phase III Comparative Study
AU  - Panuganti VK
AU  - Ghosh P
AU  - Dundigalla MR
AU  - Ramalingayya Grandhi V
AU  - Madala PK
AU  - Mohammad J
AU  - KSSVV S
AU  - Khambhampaty S
AU  - Fatima F
PY  - 2026
DA  - 2026/11/15
JO  - Drug Design, Development and Therapy
UR  - https://www.dovepress.com/efficacy-safety-and-immunogenicity-of-biosimilar-versus-reference-adal-peer-reviewed-fulltext-article-DDDT
AB  - Veerendra Kumar Panuganti,1 Parasar Ghosh,2 Mamatha Reddy Dundigalla,3 Venkata Ramalingayya Grandhi,3 Pavan Kumar Madala,4 Javeed Mohammad,1 Sanyasirao KSSVV,1 Sridevi Khambhampaty,5 Firdaus Fatima6 1Clinical Affairs Division, Shilpa Medicare Limited, Hyderabad, Telangana, 500076, India; 2Institute of Postgraduate, Medical Education and Research, Kolkata, West Bengal, 700020, India; 3Medical Affairs Department, Shilpa Medicare Limited, Hyderabad, Telangana, 500076, India; 4Bioanalytical Laboratory, Shilpa Medicare Ltd, Hyderabad, Telangana, 500076, India; 5Shilpa Biologicals Private Limited, Dharwad, Karnataka, 580011, India; 6St. Theresa’s Hospital, Hyderabad, Telangana, 500038, IndiaCorrespondence: Veerendra Kumar Panuganti, Clinical Affairs Division, Shilpa Medicare Limited, Mallapur, Nacharam, Hyderabad, Telangana, 500076, India, Email [email protected]: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by dysregulated immune responses, persistent synovial inflammation, and involvement of multiple pro-inflammatory mediators, leading to progressive joint damage. Although adalimumab has substantially improved RA management, high-cost limits patient access. Biosimilars offer accessibility, while maintaining comparable efficacy and safety.Objective: To compare efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of test adalimumab (Oriadali®) a proposed adalimumab biosimilar, with reference adalimumab (Humira®) in Indian patients with active RA inadequately controlled by methotrexate (MTX).Methods: In this prospective, randomized, double-blind, multicenter, active-controlled Phase III study, 201 patients with active RA were randomized (2:1) to receive test adalimumab (n=134) or reference adalimumab (n=67). The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response at Week 24, assessed using a pre-specified non-inferiority margin of 28%. Secondary endpoints included ACR 20 response at Week 12, ACR50/70 at Week 24, Disease Activity Score based on 28 joints (DAS-28), C-reactive protein (CRP), Health Assessment Questionnaire-Disability Index (HAQ-DI), PK, PD, safety, and immunogenicity using anti-drug antibody (ADA) assessment.Results: ACR 20 responses at Week 24 were achieved by 120/121 (99.2%) patients receiving test adalimumab and 63/63 (100.0%) patients receiving reference adalimumab (difference of − 0.01 95% CI: − 0.03 to 0.02; p=0.4693), demonstrating non-inferiority. At Week 12, ACR20 responses were achieved by 90.1% and 92.1% of patients in both groups, respectively. At Week 24, ACR50 responses were 61.2% versus 57.1%, and ACR70 responses were 32.3% versus 33.3%. DAS28, CRP and HAQ-DI improved similarly in both groups. PK exposure was comparable, with all parameters within bioequivalence limits (T/R ratio of Cmax 100.16%; AUC0–t 102.99%), Changes in IL-6, TNF- α and immunogenicity were comparable between groups. Most Adverse events (AEs) were mild to moderate, with no serious adverse events reported.Conclusion: Test adalimumab biosimilar demonstrated comparable efficacy, safety PK, PD, and immunogenicity profiles to reference adalimumab, supporting its use in patients with active RA receiving methotrexate.Trial Registration: CTRI/2021/07/034531.Keywords: RA, Adalimumab, biosimilar, test Adalimumab, reference Adalimumab, TNF-α, MTX, PK, ADA, treatment outcome
SN  - 1177-8881
ER  -